首页> 外文期刊>Cancer letters >Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase.
【24h】

Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase.

机译:使用多药耐药性(MDR1)基因shRNA和单纯疱疹病毒胸苷激酶进行联合基因治疗。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The current study was designed to evaluate the anti-tumor effects of MDR1 shRNA in combination with herpes simplex virus-thymidine kinase/ganciclovir (HSV-tk/GCV) suicide gene therapy system. Introduction of an MDR1-targeted small hairpin RNA (shMDR) markedly enhanced the intracellular accumulation of and increased sensitivity to drugs transported by P-glycoprotein. Functional TK-eGFP fusion protein expression was confirmed by Western blot analysis and ganciclovir uptake assay. Compared with GCV or doxorubicin alone, the combination of anti-cancer drug chemotherapy with GCV administration displays additive cytotoxicity in shMDR1-TK-eGFP expressing cells. These results for the first time suggest the potential of combination gene therapy using suicide gene therapy and RNAi-based gene therapy in vitro.
机译:本研究旨在评估MDR1 shRNA与单纯疱疹病毒-胸苷激酶/更昔洛韦(HSV-tk / GCV)自杀基因治疗系统联合使用的抗肿瘤作用。靶向MDR1的小发夹RNA(shMDR)的引入显着增强了P糖蛋白转运药物的细胞内积累并提高了敏感性。通过蛋白质印迹分析和更昔洛韦摄取测定法证实了功能性TK-eGFP融合蛋白表达。与单独使用GCV或阿霉素相比,将抗癌药物化学疗法与GCV联合使用可在表达shMDR1-TK-eGFP的细胞中显示出附加的细胞毒性。这些结果首次表明在体外使用自杀基因疗法和基于RNAi的基因疗法进行联合基因疗法的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号